nach oben

International Journal of Mental Health and Addiction

06.12.2024 | Original Article

The Neurobiology of Pain, Emotion, and Stress Regulation in Suicide: Role of Cannabinoid, Opioid, Vanilloid, and Galaninergic Systems – A Systematic Review of Postmortem Evidence

verfasst von: Andrea Escelsior, Riccardo Guglielmo, Alessio Zizzi, Margherita Fioravanti, James Sanvi, Gabriele Arduino, Martina Servetti, Francesco Colaci, Beatriz Pereira da Silva, Paolo Nozza, Maurizio Pompili, Mario Amore, Gianluca Serafini

Erschienen in: International Journal of Mental Health and Addiction

Einloggen, um Zugang zu erhalten

Abstract

This systematic review investigates the association between the endocannabinoid, vanilloid, opioid, and galaninergic systems and suicide, focusing on post-mortem evidence. Findings indicate increased cannabinoid receptor 1 (CB1) densities in the prefrontal cortex, particularly in individuals with alcohol use disorder and mood disorders who died by suicide. Conversely, a decrease in CB1 receptors was observed in individuals with schizophrenia treated with antipsychotics, suggesting that this reduction may be more closely related to underlying psychopathology than directly to suicidal behavior. Limited evidence on the vanilloid system suggests stress-related alterations could influence suicide, warranting further exploration. Similarly, the opioid and galaninergic systems show alterations in individuals who died by suicide, with increased mu-opioid receptor (MOR) expression possibly representing an adaptive response to altered endogenous peptide levels. The review underscores the need for more extensive research to clarify the roles of these biological pathways in suicide, advocating for studies comparing individuals who died by suicide with and without psychiatric disorders to non-psychiatric controls to advance our understanding of these complex interactions and their implications.

Nur mit Berechtigung zugänglich

Barde, S., Rüegg, J., Prud’Homme, J., Ekström, T. J., Palkovits, M., Turecki, G., Bagdy, G., Ihnatko, R., Theodorsson, E., Juhasz, G., Diaz-Heijtz, R., Mechawar, N., & Hökfelt, T. G. M. (2016a). Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proceedings of the National Academy of Sciences of the United States of America,113(52), E8472–E8481. https://doi.org/10.1073/PNAS.1617824113CrossRefPubMedPubMedCentral

Barde, S., Rüegg, J., Prud’homme, J., Ekström, T. J., Palkovits, M., Turecki, G., Bagdy, G., Ihnatko, R., Theodorsson, E., Juhasz, G., Diaz-Heijtz, R., Mechawar, N., & Hökfelt, T. G. M. (2016b). Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proceedings of the National Academy of Sciences, 113(52). https://doi.org/10.1073/pnas.1617824113

Bhatt, R. R., Haddad, E., Zhu, A. H., Thompson, P. M., Gupta, A., Mayer, E. A., & Jahanshad, N. (2023). Mapping Brain structure variability in Chronic Pain: The role of Widespreadness and Pain Type and its mediating relationship with suicide attempt. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2023.07.016CrossRefPubMed

Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biological Psychiatry,62(10), 1103–1110. https://doi.org/10.1016/j.biopsych.2006.12.001CrossRefPubMed

Caberlotto, L. (2001). Neuropeptide Y Y1 and Y2 receptor mRNA expression in the Prefrontal Cortex of Psychiatric subjects relationship of Y2 subtype to suicidal behavior. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology,25(1), 91–97. https://doi.org/10.1016/S0893-133X(00)00231-1CrossRefPubMed

Calati, R., Laglaoui Bakhiyi, C., Artero, S., Ilgen, M., & Courtet, P. (2015). The impact of physical pain on suicidal thoughts and behaviors: Meta-analyses. Journal of Psychiatric Research,71, 16–32. https://doi.org/10.1016/j.jpsychires.2015.09.004CrossRefPubMed

Chadwick, V. L., Rohleder, C., Koethe, D., & Leweke, F. M. (2020). Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Current Opinion in Psychiatry,33(1), 20–42. https://doi.org/10.1097/YCO.0000000000000562CrossRefPubMed

Chai, Y., Luo, H., Wei, Y., Chan, S. K. W., Man, K. K. C., Yip, P. S. F., Wong, I. C. K., & Chan, E. W. (2022). Risk of self-harm or suicide associated with specific drug use disorders, 2004–2016: A population‐based cohort study. Addiction,117(7), 1940–1949. https://doi.org/10.1111/add.15820CrossRefPubMed

Christensen, H., & Brittliffe, K. (2006). Online randomized controlled trial of brief and full cognitive behaviour therapy for depression. Psychological Medicine,36(12), 1737–1746. https://doi.org/10.1017/S0033291706008695CrossRefPubMed

Console-Bram, L., Marcu, J., & Abood, M. E. (2012). Cannabinoid receptors: Nomenclature and pharmacological principles. In Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2012.02.009

Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., & Di Marzo, V. (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. https://doi.org/10.1016/j.neuroscience.2006.02.074CrossRefPubMed

Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V., & Di Marzo, V. (2008). Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience. https://doi.org/10.1016/j.neuroscience.2007.11.047CrossRefPubMed

De Oliveira, P. A., Moreno, E., Casajuana-Martin, N., Casadó-Anguera, V., Cai, N. S., Camacho-Hernandez, G. A., Zhu, H., Bonifazi, A., Hall, M. D., Weinshenker, D., Newman, A. H., Logothetis, D. E., Casadó, V., Plant, L. D., Pardo, L., & Ferré, S. (2022). Preferential gs protein coupling of the galanin Gal1 receptor in the µ-opioid-Gal1 receptor heterotetramer. Pharmacological Research,182, 106322. https://doi.org/10.1016/j.phrs.2022.106322CrossRefPubMedPubMedCentral

De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.01166.xCrossRefPubMedPubMedCentral

Eggan, S. M., Hashimoto, T., & Lewis, D. A. (2008). Reduced cortical cannabinoid 1 receptor Messenger RNA and protein expression in Schizophrenia. Archives of General Psychiatry,65(7), 772. https://doi.org/10.1001/archpsyc.65.7.772CrossRefPubMedPubMedCentral

Eggan, S. M., Stoyak, S. R., Verrico, C. D., & Lewis, D. A. (2010). Cannabinoid CB1 receptor immunoreactivity in the Prefrontal cortex: Comparison of Schizophrenia and Major Depressive Disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology,35(10), 2060–2071. https://doi.org/10.1038/npp.2010.75CrossRefPubMed

El Hayek, S., Mdawar, B., & Ghossoub, E. (2022a). Substance misuse and the older offender. Clinics in Geriatric Medicine,38(1), 159–167. https://doi.org/10.1016/J.CGER.2021.07.010

El Hayek, S. A., Shatila, M. A., Adnan, J. A., Geagea, L. E., Kobeissy, F., & Talih, F. R. (2022b). Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert Review of Neurotherapeutics,22(9), 737–749. https://doi.org/10.1080/14737175.2022.2124369

Erdozain, A. M., Rubio, M., Meana, J. J., Fernández-Ruiz, J., & Callado, L. F. (2015a). Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. Journal of Psychopharmacology (Oxford England),29(11), 1137–1145. https://doi.org/10.1177/0269881115599388CrossRefPubMed

Erdozain, A. M., Rubio, M., Valdizan, E. M., Pazos, A., Meana, J. J., Fernández-Ruiz, J., Alexander, S. P. H., & Callado, L. F. (2015b). The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addiction Biology,20(4), 773–783. https://doi.org/10.1111/adb.12160CrossRefPubMed

Escelsior, A., Sterlini, B., Belvederi Murri, M., Serafini, G., Aguglia, A., Pereira da Silva, B., Corradi, A., Valente, P., & Amore, M. (2020a). Red-hot Chili Receptors: A Systematic Review of TRPV1 Antagonism in Animal Models of Psychiatric Disorders and Addiction. Behavioural Brain Research, 10, 112734. https://doi.org/10.1016/j.bbr.2020.112734. Online ahead of print.

Escelsior, A., Sterlini, B., Belvederi Murri, M., Valente, P., Amerio, A., di Brozolo, M. R., da Silva, B. P., & Amore, M. (2020c). Transient receptor potential vanilloid 1 antagonism in neuroinflammation, neuroprotection and epigenetic regulation: Potential therapeutic implications for severe psychiatric disorders treatment. Psychiatric Genetics. https://doi.org/10.1097/YPG.0000000000000249

Escelsior, A., Sterlini, B., Murri, M. B., Serafini, G., Aguglia, A., da Silva, B. P., Corradi, A., Valente, P., & Amore, M. (2020b). Red-hot Chili receptors: A systematic review of TRPV1 antagonism in animal models of psychiatric disorders and addiction. Behavioural Brain Research,393, 112734. https://doi.org/10.1016/J.BBR.2020.112734

Escelsior, A., Belvederi Murri, M., Corsini, G., Pietro, Serafini, G., Aguglia, A., Zampogna, D., Cattedra, S., Nebbia, J., Trabucco, A., Prestia, D., Olcese, M., Barletta, E., da Pereira, B., & Amore, M. (2021). Cannabinoid use and self-injurious behaviours: A systematic review and meta-analysis. Journal of Affective Disorders,278, 85–98. https://doi.org/10.1016/j.jad.2020.09.020CrossRefPubMed

Escelsior, A., Tardito, S., Sterlini, B., Altosole, T., Trabucco, A., Marozzi, V., Serafini, G., Aguglia, A., Amerio, A., Pereira, da Silva, B., Fenoglio, D., Filaci, G., Murri, M. B., & Amore, M. (2022b). Expression of type 1 cannabinoid receptor gene in bipolar disorder. Journal of Psychiatric Research, 156, 406–413. https://doi.org/10.1016/J.JPSYCHIRES.2022.10.006

Escelsior, A., Sterlini, B., Tardito, S., Altosole, T., Magioncalda, P., Martino, M., Serafini, G., Murri, M. B., Aguglia, A., Amerio, A., da Silva, B. P., Trabucco, A., Fenoglio, D., Filaci, G., & Amore, M. (2022a). Evidence of alterations of Beta-endorphin levels and Mu-opioid receptor gene expression in bipolar disorder. Psychiatry Research, 316. https://doi.org/10.1016/J.PSYCHRES.2022.114787

Escribá, P. V., Ozaita, A., & García-Sevilla, J. A. (2004). Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology,29(8), 1512–1521. https://doi.org/10.1038/SJ.NPP.1300459CrossRefPubMed

Gabilondo, A. M., Meana, J., & García-Sevilla, J. A. (1995). Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Research,682(1–2), 245–250. https://doi.org/10.1016/0006-8993(95)00333-LCrossRefPubMed

Garani, R., Watts, J. J., & Mizrahi, R. (2021). Endocannabinoid system in psychotic and mood disorders, a review of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry,106, 110096. https://doi.org/10.1016/J.PNPBP.2020.110096CrossRefPubMed

García-Gutiérrez, M. S., Navarrete, F., Navarro, G., Reyes-Resina, I., Franco, R., Lanciego, J. L., Giner, S., & Manzanares, J. (2018). Alterations in Gene and protein expression of cannabinoid CB2 and GPR55 receptors in the Dorsolateral Prefrontal cortex of suicide victims. Neurotherapeutics,15(3), 796–806. https://doi.org/10.1007/s13311-018-0610-yCrossRefPubMedPubMedCentral

Genders, S. G., Scheller, K. J., & Djouma, E. (2020). Neuropeptide modulation of addiction: Focus on galanin. Neuroscience & Biobehavioral Reviews,110, 133–149. https://doi.org/10.1016/j.neubiorev.2018.06.021CrossRef

Grabon, W., Rheims, S., Smith, J., Bodennec, J., Belmeguenai, A., & Bezin, L. (2023). CB2 receptor in the CNS: From immune and neuronal modulation to behavior. Neuroscience & Biobehavioral Reviews,150, 105226. https://doi.org/10.1016/j.neubiorev.2023.105226CrossRef

Gross-Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. (1990). Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Research,530(2), 312–316. https://doi.org/10.1016/0006-8993(90)91301-VCrossRefPubMed

Gupta, A., Gullapalli, S., Pan, H., Ramos-Ortolaza, D. L., Hayward, M. D., Low, M. J., Pintar, J. E., Devi, L. A., & Gomes, I. (2021). Regulation of opioid receptors by their endogenous opioid peptides. Cellular and Molecular Neurobiology,41(5), 1103–1118. https://doi.org/10.1007/s10571-020-01015-wCrossRefPubMedPubMedCentral

Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., Cradick, T. J., Marraffini, L. A., Bao, G., & Zhang, F. (2013b). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnology,31(9), 827–832. https://doi.org/10.1038/NBT.2647

Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., Ni, L., Walker, S. J., Mickey, B. J., Korycinski, S. T., Koeppe, R. A., Crocker, J. K., Langenecker, S. A., & Zubieta, J. K. (2013a). Response of the µ-opioid system to social rejection and acceptance. Molecular Psychiatry,18(11), 1211–1217. https://doi.org/10.1038/mp.2013.96CrossRefPubMedPubMedCentral

Hungund, B. L., Vinod, K. Y., Kassir, S. A., Basavarajappa, B. S., Yalamanchili, R., Cooper, T. B., Mann, J. J., & Arango, V. (2004). Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Molecular Psychiatry,9(2), 184–190. https://doi.org/10.1038/SJ.MP.4001376CrossRefPubMed

Hurd, Y. L., Herman, M. M., Hyde, T. M., Bigelow, L. B., Weinberger, D. R., & Kleinman, J. E. (1997). Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Molecular Psychiatry,2(6), 495–500. https://doi.org/10.1038/sj.mp.4000319CrossRefPubMed

Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016). Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research,62, 107–128. https://doi.org/10.1016/j.plipres.2016.02.002CrossRefPubMed

Jelen, L. A., Stone, J. M., Young, A. H., & Mehta, M. A. (2022). The opioid system in depression. Neurosci Biobehav Rev Sep,140, 104800. https://doi.org/10.1016/j.neubiorev.2022.104800CrossRef

Juhasz, G., Hullam, G., Eszlari, N., Gonda, X., Antal, P., Anderson, I. M., Hökfelt, T. G. M., Deakin, J. F. W., & Bagdy, G. (2014). Brain galanin system genes interact with life stresses in depression-related phenotypes. Proceedings of the National Academy of Sciences, 111(16). https://doi.org/10.1073/pnas.1403649111

Kékesi, K. A., Juhász, G., Simor, A., Gulyássy, P., Szegő, É. M., Hunyadi-Gulyás, É., Darula, Z., Medzihradszky, K. F., Palkovits, M., Penke, B., & Czurkó, A. (2012). Altered functional protein networks in the Prefrontal Cortex and amygdala of victims of suicide. Plos One,7(12), e50532. https://doi.org/10.1371/journal.pone.0050532CrossRefPubMedPubMedCentral

Kirkland, A. E., Fadus, M. C., Gruber, S. A., Gray, K. M., Wilens, T. E., & Squeglia, L. M. (2022). A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res,308, 114347. https://doi.org/10.1016/j.psychres.2021.114347CrossRefPubMed

Kleinman, J. E., Hong, J., Iadarola, M., Govoni, S., & Gillin, C. J. (1985). Neuropeptides in human brain—postmortem studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry,9(1), 91–95. https://doi.org/10.1016/0278-5846(85)90183-6CrossRefPubMed

Koivisto, A. P., Belvisi, M. G., Gaudet, R., & Szallasi, A. (2022). Advances in TRP channel drug discovery: From target validation to clinical studies. Nature Reviews Drug Discovery,21(1), 41–59. https://doi.org/10.1038/s41573-021-00268-4CrossRefPubMed

Kormos, V., Kecskés, A., Farkas, J., Gaszner, T., Csernus, V., Alomari, A., Hegedüs, D., Renner, É., Palkovits, M., Zelena, D., Helyes, Z., Pintér, E., & Gaszner, B. (2022). Peptidergic neurons of the Edinger–Westphal nucleus express TRPA1 ion channel that is downregulated both upon chronic variable mild stress in male mice and in humans who died by suicide. Journal of Psychiatry and Neuroscience,47(3), E162–E175. https://doi.org/10.1503/jpn.210187CrossRefPubMedPubMedCentral

Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. In Biological Psychiatry.https://doi.org/10.1016/j.biopsych.2015.07.028

Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015a). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience. https://doi.org/10.1038/nrn4036CrossRefPubMedPubMedCentral

Lutz, P. E., Zhou, Y., Labbe, A., Mechawar, N., & Turecki, G. (2015b). Decreased expression of nociceptin/orphanin FQ in the dorsal anterior cingulate cortex of suicides. European Neuropsychopharmacology,25(11), 2008–2014. https://doi.org/10.1016/j.euroneuro.2015.08.015CrossRefPubMedPubMedCentral

Lutz, P. E., Gross, J. A., Dhir, S. K., Maussion, G., Yang, J., Bramoulle, A., Meaney, M. J., & Turecki, G. (2018). Epigenetic regulation of the Kappa Opioid receptor by child abuse. Biological Psychiatry,84(10), 751–761. https://doi.org/10.1016/J.BIOPSYCH.2017.07.012CrossRefPubMed

Lutz, P. E., Chay, M. A., Pacis, A., Chen, G. G., Aouabed, Z., Maffioletti, E., Théroux, J. F., Grenier, J. C., Yang, J., Aguirre, M., Ernst, C., Redensek, A., van Kempen, L. C., Yalcin, I., Kwan, T., Mechawar, N., Pastinen, T., & Turecki, G. (2021). Non-CG methylation and multiple histone profiles associate child abuse with immune and small GTPase dysregulation. Nature Communications,12(1), 1132. https://doi.org/10.1038/s41467-021-21365-3CrossRefPubMedPubMedCentral

Mangieri, R. A., & Piomelli, D. (2007). Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacological Research,56(5), 360–366. https://doi.org/10.1016/j.phrs.2007.09.003CrossRefPubMedPubMedCentral

Mato, S., Pilar-Cuéllar, F., Valdizán, E. M., González-Maeso, J., Rodríguez-Puertas, R., Meana, J., Sallés, J., Crespo-Facorro, B., & Pazos, Á. (2018). Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders. Biochemical Pharmacology,157, 258–265. https://doi.org/10.1016/j.bcp.2018.08.012CrossRefPubMedPubMedCentral

Meier, I. M., van Honk, J., Bos, P. A., & Terburg, D. (2021). A mu-opioid feedback model of human social behavior. Neuroscience & Biobehavioral Reviews,121, 250–258. https://doi.org/10.1016/j.neubiorev.2020.12.013CrossRef

Mlost, J., Wąsik, A., & Starowicz, K. (2019). Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain. Pharmacological Research,143, 40–47. https://doi.org/10.1016/j.phrs.2019.02.029CrossRefPubMed

Muller, C., Morales, P., & Reggio, P. H. (2019). Cannabinoid Ligands Targeting TRP Channels. Frontiers in Molecular Neuroscience,11, 487. https://doi.org/10.3389/fnmol.2018.00487CrossRefPubMedPubMedCentral

Neuberger, A., Oda, M., Nikolaev, Y. A., Nadezhdin, K. D., Gracheva, E. O., Bagriantsev, S. N., & Sobolevsky, A. I. (2023a). Human TRPV1 structure and inhibition by the analgesic SB-366791. Nature Communications,14(1), 2451. https://doi.org/10.1038/s41467-023-38162-9

Neuberger, A., Oda, M., Nikolaev, Y. A., Nadezhdin, K. D., Gracheva, E. O., Bagriantsev, S. N., & Sobolevsky, A. I. (2023b). Human TRPV1 structure and inhibition by the analgesic SB-366791. Nature Communications, 14(1). https://doi.org/10.1038/S41467-023-38162-9

Nobile, B., Ramoz, N., Jaussent, I., Gorwood, P., Olié, E., Castroman, J. L., Guillaume, S., & Courtet, P. (2019a). Polymorphism A118G of opioid receptor mu 1 (OPRM1) is associated with emergence of suicidal ideation at antidepressant onset in a large naturalistic cohort of depressed outpatients. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-39622-3

Nobile, B., Ramoz, N., Jaussent, I., Gorwood, P., Olié, E., Castroman, J. L., Guillaume, S., & Courtet, P. (2019b). Polymorphism A118G of opioid receptor mu 1 (OPRM1) is associated with emergence of suicidal ideation at antidepressant onset in a large naturalistic cohort of depressed outpatients. Scientific Reports,9(1), 1–8. https://doi.org/10.1038/s41598-019-39622-3

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Bmj,71, n71. https://doi.org/10.1136/bmj.n71CrossRef

Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017). The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2016.12.033

Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J. K. (2019a). Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. In Molecular Psychiatry (Vol. 24, Issue 4, pp. 576–587). Nature Publishing Group. https://doi.org/10.1038/s41380-018-0117-2

Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J. K. (2019b). Endogenous opioid system dysregulation in depression: Implications for new therapeutic approaches. Molecular Psychiatry,24(4), 576–587. https://doi.org/10.1038/S41380-018-0117-2

Peters, K. Z., Cheer, J. F., & Tonini, R. (2021a). Modulating the neuromodulators: Dopamine, serotonin, and the Endocannabinoid System. Trends in Neurosciences,44(6), 464–477. https://doi.org/10.1016/j.tins.2021.02.001

Peters, K. Z., Oleson, E. B., & Cheer, J. F. (2021b). A brain on cannabinoids: The role of dopamine release in reward seeking and addiction. Cold Spring Harbor Perspectives in Medicine, 11(1), 1–18. https://doi.org/10.1101/CSHPERSPECT.A039305CrossRef

Prospéro-García, O., Amancio-Belmont, O., Meléndez, B., Ruiz-Contreras, A. L., & Méndez-Díaz, M. (2016). Endocannabinoids and sleep. Neuroscience & Biobehavioral Reviews,71, 671–679. https://doi.org/10.1016/j.neubiorev.2016.10.005CrossRef

Rana, T., Behl, T., Sehgal, A., Singh, S., Sharma, N., Abdeen, A., Ibrahim, S. F., Mani, V., Iqbal, M. S., Bhatia, S., Abdel Daim, M. M., & Bungau, S. (2022). Exploring the role of neuropeptides in depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry,114, 110478. https://doi.org/10.1016/j.pnpbp.2021.110478CrossRefPubMed

Richardson, E., DePue, M. K., Therriault, D. J., Alli, S., & Liu, R. (2020). The influence of Substance Use on Engagement in Non-suicidal Self-Injury (NSI) in adults. Substance Use & Misuse,55(1), 89–94. https://doi.org/10.1080/10826084.2019.1656254CrossRef

Rizk, M. M., Herzog, S., Dugad, S., & Stanley, B. (2021). Suicide risk and addiction: The impact of Alcohol and Opioid Use disorders. Current Addiction Reports,8(2), 194–207. https://doi.org/10.1007/s40429-021-00361-zCrossRefPubMedPubMedCentral

Rizvi, S. J., Gandhi, W., & Salomons, T. (2021). Reward processing as a common diathesis for chronic pain and depression. Neuroscience & Biobehavioral Reviews,127, 749–760. https://doi.org/10.1016/j.neubiorev.2021.04.033CrossRef

Rocchi, G., Sterlini, B., Tardito, S., Inglese, M., Corradi, A., Filaci, G., Amore, M., Magioncalda, P., & Martino, M. (2020). Opioidergic System and Functional Architecture of intrinsic brain activity: Implications for Psychiatric disorders. The Neuroscientist,26(4), 343–358. https://doi.org/10.1177/1073858420902360CrossRefPubMed

Salort, G., Hernández-Hernández, E., García-Fuster, M. J., & García-Sevilla, J. A. (2020). Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder. Journal of Affective Disorders,276, 626–635. https://doi.org/10.1016/j.jad.2020.07.074CrossRefPubMed

Scarone, S., Gambini, O., Calabrese, G., Sacerdote, P., Bruni, M., Carucci, M., & Panerai, A. E. (1990). Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: Preliminary data. Psychiatry Research, 32(2), 159–166. https://doi.org/10.1016/0165-1781(90)90082-G

Scarr, E., Sundram, S., Deljo, A., Cowie, T. F., Gibbons, A. S., Juzva, S., Mackinnon, A., Wood, S. J., Testa, R., Pantelis, C., & Dean, B. (2012). Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. Schizophrenia Research,138(1), 94–98. https://doi.org/10.1016/j.schres.2012.02.011CrossRefPubMed

Scherer, P. C., Zaccor, N. W., Neumann, N. M., Vasavda, C., Barrow, R., Ewald, A. J., Rao, F., Sumner, C. J., & Snyder, S. H. (2017). TRPV1 is a physiological regulator of µ-opioid receptors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1717005114

Schwartz, N., Temkin, P., Jurado, S., Lim, B. K., Heifets, B. D., Polepalli, J. S., & Malenka, R. C. (2014). Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens. Science,345(6196), 535–542. https://doi.org/10.1126/science.1253994CrossRefPubMedPubMedCentral

Shamabadi, A., Ahmadzade, A., Pirahesh, K., Hasanzadeh, A., & Asadigandomani, H. (2023). Suicidality risk after using cannabis and cannabinoids: An umbrella review. Dialogues in Clinical Neuroscience,25(1), 50–63. https://doi.org/10.1080/19585969.2023.2231466CrossRefPubMedPubMedCentral

Sharma, A., Ren, X., Zhang, H., & Pandey, G. N. (2022a). Effect of depression and suicidal behavior on neuropeptide Y (NPY) and its receptors in the adult human brain: A postmortem study. Progress in Neuro-Psychopharmacology and Biological Psychiatry,112, 110428. https://doi.org/10.1016/j.pnpbp.2021.110428

Sharma, A., Ren, X., Zhang, H., & Pandey, G. N. (2022b). Effect of depression and suicidal behavior on neuropeptide Y (NPY) and its receptors in the adult human brain: A postmortem study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 112. https://doi.org/10.1016/J.PNPBP.2021.110428

Urigüen, L., García-Fuster, M. J., Callado, L. F., Morentin, B., La Harpe, R., Casadó, V., Lluis, C., Franco, R., García-Sevilla, J. A., & Meana, J. J. (2009). Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment. Psychopharmacology (Berl),206(2), 313–324. https://doi.org/10.1007/S00213-009-1608-2CrossRefPubMed

Vinod, K. Y., Arango, V., Xie, S., Kassir, S. A., Mann, J. J., Cooper, T. B., & Hungund, B. L. (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biological Psychiatry,57(5), 480–486. https://doi.org/10.1016/j.biopsych.2004.11.033CrossRefPubMed

Vinod, K. Y., Kassir, S. A., Hungund, B. L., Cooper, T. B., Mann, J. J., & Arango, V. (2010). Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. Journal of Psychiatric Research,44(9), 591–597. https://doi.org/10.1016/j.jpsychires.2009.11.013CrossRefPubMed

Volkow, N. D., Hampson, A. J., & Baler, R. D. (2017). Don’t Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward. 57, 285–308. https://doi.org/10.1146/ANNUREV-PHARMTOX-010716-104615

Wang, P., Li, H., Barde, S., Zhang, M. D., Sun, J., Wang, T., Zhang, P., Luo, H., Wang, Y., Yang, Y., Wang, C., Svenningsson, P., Theodorsson, E., Hökfelt, T. G. M., & Xu, Z. Q. D. (2016). Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. Proceedings of the National Academy of Sciences, 113(32). https://doi.org/10.1073/pnas.1609198113

WHO. (2021). Suicide worldwide in 2019: Global health estimates. World Health Organization. Licence: CC BY-NC-SA3.0 IGO

Widdowson, P. S., Ordway, G. A., & Halaris, A. E. (1992). Reduced neuropeptide Y concentrations in suicide brain. Journal of Neurochemistry,59(1), 73–80. https://doi.org/10.1111/j.1471-4159.1992.tb08877.xCrossRefPubMed

Zádor, F., & Wollemann, M. (2015). Receptome: Interactions between three pain-related receptors or the triumvirate of cannabinoid, opioid and TRPV1 receptors. In Pharmacological Research. https://doi.org/10.1016/j.phrs.2015.10.015

Zalsman, G., Molcho, A., Huang, Y., Dwork, A., Li, S., & Mann, J. J. (2005). Postmortem µ-opioid receptor binding in suicide victims and controls. Journal of Neural Transmission,112(7), 949–954. https://doi.org/10.1007/s00702-004-0239-3CrossRefPubMed

Zhong, W., Barde, S., Mitsios, N., Adori, C., Oksvold, P., von Feilitzen, K., O’Leary, L., Csiba, L., Hortobágyi, T., Szocsics, P., Mechawar, N., Maglóczky, Z., Renner, É., Palkovits, M., Uhlén, M., Mulder, J., & Hökfelt, T. (2022). The neuropeptide landscape of human prefrontal cortex. Proceedings of the National Academy of Sciences, 119(33). https://doi.org/10.1073/pnas.2123146119

Titel: The Neurobiology of Pain, Emotion, and Stress Regulation in Suicide: Role of Cannabinoid, Opioid, Vanilloid, and Galaninergic Systems – A Systematic Review of Postmortem Evidence
verfasst von: Andrea Escelsior
Riccardo Guglielmo
Alessio Zizzi
Margherita Fioravanti
James Sanvi
Gabriele Arduino
Martina Servetti
Francesco Colaci
Beatriz Pereira da Silva
Paolo Nozza
Maurizio Pompili
Mario Amore
Gianluca Serafini
Publikationsdatum: 06.12.2024
Verlag: Springer US
Erschienen in: International Journal of Mental Health and Addiction
Print ISSN: 1557-1874
Elektronische ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-024-01419-5

Neu im Fachgebiet Psychiatrie

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Depressive Senioren fahren besonders riskant

14.01.2025
Altersdepression
Nachrichten

Beim Autofahren machen ältere Depressive häufiger eine Vollbremsung, gehen öfter zu schnell in Kurven und halten sich seltener an Tempolimits als Senioren ohne Depression. Offenbar scheint eine Depression eine riskante Fahrweise im Alter zu verstärken.

Verhaltenstherapie plus Stimulanz reduziert Binge Eating

14.01.2025
Binge-Eating-Störung
Nachrichten

Die Kombination von kognitiver Verhaltenstherapie plus Lisdexamfetamin bringt Personen mit Binge-Eating-Störung deutlich häufiger in Remission als die jeweiligen Einzeltherapien. Zudem nimmt das Gewicht der Betroffenen spürbar ab.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen